Verve Therapeutics (NASDAQ:VERV) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Verve Therapeutics (NASDAQ:VERVFree Report) in a report published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $22.00 target price on the stock.

A number of other research firms have also weighed in on VERV. Guggenheim lowered their price target on shares of Verve Therapeutics from $56.00 to $55.00 and set a buy rating on the stock in a research report on Tuesday, August 15th. Credit Suisse Group restated a neutral rating and issued a $31.00 price target on shares of Verve Therapeutics in a research report on Friday, August 11th. Finally, Lifesci Capital reiterated an outperform rating on shares of Verve Therapeutics in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $30.83.

Read Our Latest Stock Report on VERV

Verve Therapeutics Price Performance

Shares of Verve Therapeutics stock opened at $13.00 on Wednesday. The stock has a market capitalization of $828.37 million, a P/E ratio of -4.10 and a beta of 1.70. The business has a 50 day simple moving average of $16.76 and a two-hundred day simple moving average of $16.78. Verve Therapeutics has a 12 month low of $11.97 and a 12 month high of $41.96.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.03. Verve Therapeutics had a negative return on equity of 37.08% and a negative net margin of 3,534.98%. The firm had revenue of $2.10 million during the quarter, compared to the consensus estimate of $0.67 million. The firm’s quarterly revenue was up 2000.0% on a year-over-year basis. As a group, research analysts anticipate that Verve Therapeutics will post -3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. CI Investments Inc. purchased a new stake in Verve Therapeutics in the fourth quarter valued at $44,000. Amundi purchased a new stake in Verve Therapeutics in the 4th quarter valued at about $45,000. Penserra Capital Management LLC acquired a new position in Verve Therapeutics in the first quarter valued at about $46,000. Point72 Asset Management L.P. lifted its position in Verve Therapeutics by 2,521.0% in the second quarter. Point72 Asset Management L.P. now owns 3,250 shares of the company’s stock valued at $61,000 after buying an additional 3,126 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Verve Therapeutics by 133.4% during the first quarter. Ameritas Investment Partners Inc. now owns 2,827 shares of the company’s stock worth $65,000 after buying an additional 1,616 shares during the period. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

(Get Free Report)

Verve Therapeutics, Inc, a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.

Further Reading

Analyst Recommendations for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with's FREE daily email newsletter.